Skip Navigation

European Heart Journal 2001 22(13):1065-1066; doi:10.1053/euhj.2000.2702
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mulcahy, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mulcahy, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorials

Statins and cardiovascular disease—major therapeutic advances but are we seizing the moment?

D. Mulcahy

Tallaght Hospital, Dublin, Ireland

References

  1. Lancet. 1994;344:1383–1389[CrossRef][ISI][Medline]
  2. Shepherd J, Cobbe Sm, Ford I. Prevention of coronary disease with Pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307[Abstract/Free Full Text]
  3. Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009[Abstract/Free Full Text]
  4. N Engl J Med. 1998;339:1349–1357[Abstract/Free Full Text]
  5. Downs JR, Clearfield M, Weis S. JAMA. 1998;279:615–622[Free Full Text]
  6. Byington RP, Davis BR, Plehn JF. Reduction of stroke events with Pravastatin: The Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001;103:387–392[Abstract/Free Full Text]
  7. Wilhelmsen L, Pyörälä K, Wedel H, Cook T, Pedersen T, Kjekshus J. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S); impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J. 2001;22:1119–1127[Abstract/Free Full Text]
  8. Gotto AM, Whitney E, Stein EA. Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCaps). Eur Heart J. 2000;21:1627–1633[Abstract/Free Full Text]
  9. Daly C, Mulcahy D. Lipid lowering in acute coronary syndromes—is it ever too early for treatment. Br J Cardiol. 2000;7:8–10

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mulcahy, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mulcahy, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?